|
"kung hj"的相關文件
顯示項目 6-15 / 90 (共9頁)
1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2023-09-15 |
REST-repressed lncRNA LINC01801 induces neuroendocrine differentiation in prostate cancer via transcriptional activation of autophagy
|
Chang, CH;Cheng, TY;Yeh, WW;Luo, YL;Campbell, M;Kuo, TC;Shen, TW;Hong, YC;Tsai, CH;Peng, YC;Pan, CC;Yang, MH;Shih, JC;Kung, HJ;Huang, WJ;Chang, PC;Lin, TP |
| 國家衛生研究院 |
2023-09-01 |
Method and composition for decreasing the pschotomimetic and addictive disorder of ketamine
|
Chen, HH;Kung, HJ |
| 國家衛生研究院 |
2023-04 |
Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer
|
Hung, CL;Liu, HH;Fu, CW;Yeh, HH;Hu, TL;Kuo, ZK;Lin, YC;Jhang, MR;Hwang, CS;Hsu, HC;Kung, HJ;Wang, LY |
| 國家衛生研究院 |
2023-03-21 |
Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
|
Chen, HH;Kung, HJ |
| 國家衛生研究院 |
2022-05-09 |
Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer
|
Liu, JS;Fang, WK;Yang, SM;Wu, MC;Chen, TJ;Chen, CM;Lin, TY;Liu, KL;Wu, CM;Chen, YC;Chuu, CP;Wang, LY;Hsieh, HP;Kung, HJ;Wang, WC |
| 國家衛生研究院 |
2022-05-05 |
TEAD4 as an oncogene and a mitochondrial modulator
|
Hsu, SC;Lin, CY;Lin, YY;Collins, CC;Chen, CL;Kung, HJ |
| 國家衛生研究院 |
2022-03 |
Inhibition of KDM4C/c-Myc/LDHA signalling axis suppresses prostate cancer metastasis via interference of glycolytic metabolism
|
Lin, CY;Wang, BJ;Fu, YK;Huo, C;Wang, YP;Chen, BC;Liu, WY;Tseng, JC;Jiang, SS;Sie, ZL;Tsai, KK;Yuh, CH;Wang, WC;Kung, HJ;Chuu, CP |
| 國家衛生研究院 |
2021-12-14 |
Targeting mitochondrial OXPHOS and their regulatory signals in prostate cancers
|
Chen, C;Lin, C;Kung, HJ |
| 國家衛生研究院 |
2021-11 |
Human iPSC-derived neurons as a platform for deciphering the mechanisms behind brain aging
|
Chao, CC;Shen, PW;Tzeng, TY;Kung, HJ;Tsai, TF;Wong, YH |
| 國家衛生研究院 |
2021-08-12 |
Prognostic significance of o-glcnac and PKM2 in hormone receptor-positive and HER2-nonenriched breast cancer
|
Kuo, WL;Tseng, LL;Chang, CC;Chen, CJ;Cheng, ML;Cheng, HH;Wu, MJ;Chen, YL;Chang, RT;Tang, HY;Hsu, YC;Lin, WJ;Kao, CY;Hsieh, WP;Kung, HJ;Wang, WC |
顯示項目 6-15 / 90 (共9頁)
1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
